VALENCIA, Calif., MELBOURNE, Australia & AURORA, Colo.--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, and scientists at the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine announced today a preclinical research collaboration to establish proof-of-concept and explore further development of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa (EB), with potential applicability to other genetic skin disorders.
The partnership will pair AVITA Medicals patented and proprietary Spray-On Skin Cells technology and expertise with the Gates Centers innovative, patent-pending combined reprogramming and gene-editing technology to allow cells to function properly. Under the terms of the Sponsored Research Agreement (SRA), AVITA Medical retains the option to exclusively license technologies emerging from the partnership for further development and commercialization. The Gates Center team is further supported by the EB Research Partnership in New York, the Los Angeles-based EB Medical Research Foundation, the London-based Cure EB Charity, and government grants in a collaborative effort to rapidly develop and translate this technology to the clinic for meaningful impact on patient lives.
The Gates Center is a leader in developing therapeutic approaches for genetic skin diseases. Researchers at the Gates Center have developed a powerful new approach for treating genetic skin disorders and improving the lives of patients with epidermolysis bullosa, said Dr. Mike Perry, Chief Executive Officer of AVITA Medical and adjunct professor at the Gates Center for Regenerative Medicine. We look forward to collaborating with the team at the Gates Center on the expanded use of our technology. This agreement marks an important milestone in AVITAs mission to harness the potential of regenerative medicine to address unmet medical needs across a broad range of dermatological indications, including genetic disorders of the skin.
Epidermolysis bullosa is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death. There are no approved curative therapies, and current treatment is palliativefocused primarily on pain and nutritional management, itching relief, wound care, and bandaging.
Its very exciting to partner with AVITA Medical to help advance our epidermolysis bullosa program, said Director of the Gates Center for Regenerative Medicine Dr. Dennis Roop. Were looking forward to exploring a novel approach to delivering gene-edited skin cells to patients that addresses current treatment challenges.
We believe that Spray-On Skin Cells technology combined with our genetically corrected cells has the potential to be game changing in the treatment of this disease. This combination could reduce time to treatment, lower manufacturing complexity, reduce costs, and improve patient outcomes, said Dr. Ganna Bilousova, assistant professor of dermatology, who is a co-principal investigator on this research program.
ABOUT THE CHARLES C. GATES CENTER FOR REGENERATIVE MEDICINE
The Charles C. Gates Center for Regenerative Medicine was established in 2006 with a gift in memory of Denver industrialist and philanthropist Charles C. Gates, who was captivated by the hope and benefit stem cell research promised for so many people in the world. The Gates Center aspires to honor what he envisionedby doing everything possible to support the collaboration between basic scientific researchers and clinical faculty to transition scientific breakthroughs into clinical practice as quickly as possible.
Led by Founding Director Dennis Roop, Ph.D., the Gates Center is located at the University of Colorados Anschutz Medical Campus, the largest new biomedical and clinical campus in the United States. Operating as the only comprehensive Stem Cell Center within a 500-mile radius, the Gates Center shares its services and resources with an ever-enlarging membership of researchers and clinicians at the Anschutz Medical Campus, which includes University of Colorado Hospital, Childrens Hospital Colorado, and the Veterans Administration Medical Center, as well as the Boulder campus, Colorado State University, the Colorado School of Mines, and business startups. This collaboration is designed to draw on the widest possible array of scientific exploration relevant to stem cell technology focused on the delivery of innovative therapies in Colorado and beyond.
ABOUT THE UNIVERSITY OF COLORADO SCHOOL OF MEDICINE
Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators, and scientists at University of Colorado Hospital, Childrens Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the Anschutz Medical Campus, one of four campuses in the University of Colorado system. To learn more about the medical schools care, education, research, and community engagement, visit its web site.
ABOUT AVITA MEDICAL LIMITED
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. Burn Centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information, including contraindications, warnings, and precautions.
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications, including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.
To learn more, visit http://www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
- The Center for Breakthrough Medicines is Building the World's Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO)... - January 22nd, 2020
- Toxys Strengthens Leadership Team with Appointment of CBO and COO Positions - BioSpace - January 22nd, 2020
- Share the Love on Valentine's Day! Join the Cure 4 The Kids Foundation Blood Drive and Registry Event - Nevada Business Magazine - January 22nd, 2020
- Botox, medical drips and more offered at NVY Center - SILive.com - January 18th, 2020
- Walter named Edward P. Evans Endowed Professor - Washington University School of Medicine in St. Louis - January 18th, 2020
- Who are the 10 Most Innovative Biopharma Companies? - BioSpace - January 18th, 2020
- Using RNA as a Delivery Vehicle Is the Magic Bullet to Cure Gene Mutation - Science Times - January 13th, 2020
- The F.D.A. Is in Trouble. Heres How to Fix It. - The New York Times - January 12th, 2020
- Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami - Yahoo Finance - January 10th, 2020
- John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise - January 10th, 2020
- Orgenesis Announces Addition of University of California, Davis, to its Point of Care Network; UC Davis Health to Utilize Orgenesis Point of Care... - January 10th, 2020
- Aspen Neuroscience Announces Board of Directors and Scientific Advisory Board - PRNewswire - January 10th, 2020
- How Kyoto Is Rebuilding Itself As A Nanotech And Regenerative Medicine Powerhouse - Forbes - January 10th, 2020
- ASH 2019 | The impact of donor clonal hematopoiesis on aGvHD and patient outcomes - AML Global Portal - January 9th, 2020
- New protocol could signal shift in bone regenerative medicine - PR Web - January 7th, 2020
- Stem Cell Alopecia Treatment Market 2020 Size, Share Metrics, Growth Trends and Forecast to 2026 - Pro News Time - January 7th, 2020
- Firm adds a new wrinkle to anti-aging products - The Logan Banner - January 1st, 2020
- The Major Discoveries That Could Transform the World in the Next Decade - Livescience.com - January 1st, 2020
- Alligator Skin, Human Clones and Other Things Being Banned in 2020 - The New York Times - December 31st, 2019
- ESPN reporter Edward Aschoff diagnosed with pneumonia and HLH before he died - WPVI-TV - December 31st, 2019
- ESPN reporter Edward Aschoff was diagnosed with pneumonia and HLH before he died. What is HLH? - Q13 News Seattle - December 29th, 2019
- The top 45 stories of the decade - ISRAEL21c - December 29th, 2019
- ESPN reporter diagnosed with pneumonia, HLH. What is HLH? - KXLY Spokane - December 27th, 2019
- Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT - Dove Medical Press - December 19th, 2019
- Stem Cell Therapy is a Must Try Method for Permanent Relief from Pain, Says Integrated Medical Center of Corona - Press Release - Digital Journal - December 19th, 2019
- Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center Become Associate Members of the New York Genome Center - BioSpace - December 19th, 2019
- Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc - OrthoSpineNews - December 19th, 2019
- Experts and Attitude Help Grandfather Face Primary Central Nervous System Lymphoma - Dana-Farber Cancer Institute - December 19th, 2019
- 100 hospitals and health systems with great neurosurgery and spine programs | 2019 - Becker's Hospital Review - December 14th, 2019
- Therapeutic Exosomes Go From Vein to Brain - Technology Networks - December 13th, 2019
- Blinatumomab May Become New Standard of Care for Post-Reinduction Therapy in Young Patients With B-ALL - Cancer Therapy Advisor - December 13th, 2019
- Deacon Butch King learns to accept the 'gift' of cancer - Arkansas Catholic - December 13th, 2019
- How cancer cells grow and spread in colon tissue? - Tech Explorist - December 5th, 2019
- Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? - Kaiser Health News - December 5th, 2019
- Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer - PRNewswire - December 5th, 2019
- Analysis Shows Need for Better Classification of Rare Lymphoma - Patch.com - December 5th, 2019
- Aledo and Ennis will be a legendary regional final matchup, and not because of what's on the playing field - The Dallas Morning News - December 5th, 2019
- Volumetric Bioprinting: The New Paradigm in Regenerative Medicine - Advanced Science News - December 2nd, 2019
- Heres what you might have missed from the week in business - The Boston Globe - December 2nd, 2019
- Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - PRNewswire - November 29th, 2019
- The FutureAnd the End?of AIDS - Columbia University Irving Medical Center - November 29th, 2019
- Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market - P&T Community - November 29th, 2019
- ENCORE: Why There Are So Few Black Men In Medicine; Family of Stem Cell Donor Connects With Recipient 20 Years Later; Forecasting Volcanic Eruptions -... - November 26th, 2019
- Trial cancer treatment in Wichita - KAKE - November 26th, 2019
- Personalized Stem Cells, Inc. Sponsors Arthritis Foundation Event in Los Angeles - PR Web - November 26th, 2019
- BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York - P&T Community - November 26th, 2019
- Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more - Newswise - November 22nd, 2019
- ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial - ALS News Today - November 22nd, 2019
- Stem Cell Alopecia Treatment Market: moving from experimentation to transformation in 2024 - WindStreetz - November 22nd, 2019
- For veterans, theres no better cause to push than helping other vets - Snoqualmie Valley Record - November 18th, 2019
- What to Know in Washington: Trump Ally in Impeachment Spotlight - Bloomberg Government - November 18th, 2019
- Possible Treatment Found for Contractures in CP, Childhood Paralysis, Early Study Shows - Cerebral Palsy News Today - November 14th, 2019
- Asia's Top Firms Recognized at the 2019 Frost & Sullivan Asia-Pacific Best Practices Awards - Yahoo Finance - November 14th, 2019
- Takeda, Anderson Cancer Center team up for cell therapy - BSA bureau - November 11th, 2019
- Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform - BioSpace - November 11th, 2019
- Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And | CMAR - Dove Medical Press - November 8th, 2019
- An artist and a transplant researcher discuss the heart - Harvard Gazette - November 8th, 2019
- 2019s Allen Distinguished Investigators will focus on the mysteries of our cells - GeekWire - November 6th, 2019
- Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights - P&T Community - November 6th, 2019
- Cost is a major challenge in stem cells therapy: Dr Na'eem Sadiq - ETHealthworld.com - November 6th, 2019
- Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of... - November 6th, 2019
- Cardon Children's is proud of its 10-year history - East Valley Tribune - November 6th, 2019
- Celebrating Cancer Heroes will recognize survivors at event in Somers - Reminder Publications - November 6th, 2019
- Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Yahoo Finance - November 6th, 2019
- MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform - Newswise - November 6th, 2019
- Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune... - November 6th, 2019
- Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting - Business... - November 6th, 2019
- New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients - Bradford Era - November 5th, 2019
- VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web - November 5th, 2019
- Create a fetus without an egg or sperm? Researchers have done it with mice - Genetic Literacy Project - November 5th, 2019
- Cellular Biomedicine Group to Report Third Quarter 2019 Results on November 6, 2019 - Olean Times Herald - November 3rd, 2019
- Three UCLA scientists receive grants totaling more than $18 million - Newswise - October 31st, 2019
- Doheny and UCLA Stein Eye Institutes Welcome Kaustabh Ghosh, PhD, to the Scientific and Clinical Research Faculty - PRNewswire - October 31st, 2019
- bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Yahoo Finance - October 31st, 2019
- BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019 - PRNewswire - October 31st, 2019
- Introducing: iPSC Collection from Tauopathy Patients - Alzforum - October 24th, 2019
- Artificial embryo without sperm or egg forms live fetus - ZME Science - October 21st, 2019
- Novel Cell Sorting and Separation Markets, 2030 - Yahoo Finance - October 7th, 2019
- Platelet BioGenesis Receives Contract Worth Up to $56 Million from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human... - October 7th, 2019
- Researchers identify molecular process that could accelerate recovery from nerve injuries - UCLA Newsroom - October 7th, 2019